Treatment of glycogen storage disease type II
AssigneeDuke University
InventorYuan-Tsong Chen
Life of this patent
Estimating the term…
Abstract
Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.
Claims19
A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual human acid α-glucosidase produced in chinese hamster ovary cell cultures, in a therapeutically effective amount that is sufficient to increase end-diastolic and/or end-systolic ventricular volume over baseline measurement of said volume in the individual.
A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual human acid α-glucosidase produced in chinese hamster ovary cell cultures, in a therapeutically effective amount that is sufficient to decrease left ventricular mass from baseline measurement of said mass in the individual.
A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual human acid α-glucosidase produced in chinese hamster ovary cell cultures, in a therapeutically effective amount that is sufficient to increase pulmonary function over baseline capacity in the individual.
A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual human acid α-glucosidase produced in chinese hamster ovary cell cultures, in a therapeutically effective amount sufficient to improve motor development over baseline measurement of motor development in the individual.
A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual human acid α-glucosidase produced in chinese hamster ovary cell cultures, in a therapeutically effective amount sufficient to improve neurodevelopment over baseline measurement of neurodevelopment in the individual.
Dependencies are inferred from the claim text.